Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1205704 | 0.79 | USP2 (0.45) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL6496032 | 0.78 | USP2 (0.39) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL3585566 | 0.77 | ALDH1A1 (0.48) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL3586435 | 0.77 | ALDH1A1 (0.48) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL711729 | 0.77 | ALDH1A1 (0.48) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL21796461 | 0.73 | ALDH1A1 (0.34) | TSHRALDH1A1 | |
| SCHEMBL17183874 | 0.70 | ALDH1A1 (0.46) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL546080 | 0.70 | USP2 (0.36) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL3825698 | 0.68 | ALDH1A1 (0.43) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL6649846 | 0.67 | ALDH1A1 (0.37) | USP2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE38934-E1 | Method and reagents for N-alkylating ureides | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-01-10 | — | — | US | claimed |
| US-20040167358-A1 | Method and reagents for N-alkylating ureides | GUTMAN DANIELA (IL) | 2004-08-26 | — | — | US | claimed |
| EP-1027339-B1 | METHOD AND REAGENTS FOR N-ALKYLATING UREIDES | TARO PHARMA IND (IL) | 2004-01-02 | — | — | EP | claimed |
| US-20030018080-A1 | N-methoxymethyl-5,5-diphenylbarbituric acid | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-23 | — | — | US | claimed |
| CN-1273581-A | Process and reagent for N-alkylation of ureides | TARO PHARMA IND (IL) | 2000-11-15 | — | — | CN | claimed |
| US-6093820-A | REACTING AN IMIDE WITH A (SUBSTITUTED)ALKOXYALKYLSULFONIC ACID ESTER TO FORM A N-ALKOXYALKYL IMIDE SUCH AS METHOXYMETHYL ETHOSUXIMIDE; ADMINISTERING AS ANTICONVULSANT, ANTIANXIETY AGENT AND MUSCLE RELAXANT | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2000-07-25 | — | — | US | claimed |
| US-RE38934-E1 | Method and reagents for N-alkylating ureides | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-01-10 | — | — | US | disclosed |
| US-6906079-B2 | Method and reagents for N-alkylating ureides | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2005-06-14 | — | — | US | disclosed |
| EP-1027339-B1 | METHOD AND REAGENTS FOR N-ALKYLATING UREIDES | TARO PHARMA IND (IL) | 2004-01-02 | — | — | EP | disclosed |
| US-6664262-B2 | N-methoxymethyl-5,5-diphenylbarbituric acid | TARO PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2003-12-16 | — | — | US | disclosed |
| EP-1342718-A1 | Method and reagents for n-alkylating ureides | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2003-09-10 | — | — | EP | disclosed |
| US-6093820-A | REACTING AN IMIDE WITH A (SUBSTITUTED)ALKOXYALKYLSULFONIC ACID ESTER TO FORM A N-ALKOXYALKYL IMIDE SUCH AS METHOXYMETHYL ETHOSUXIMIDE; ADMINISTERING AS ANTICONVULSANT, ANTIANXIETY AGENT AND MUSCLE RELAXANT | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2000-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018080-A1 | N-methoxymethyl-5,5-diphenylbarbituric acid | MGMT, ALKBH3, ALKBH5 | USP2 1135/4885TSHR 3284/4885ALDH1A1 406/4885 |
| US-20040167358-A1 | Method and reagents for N-alkylating ureides | MGMT, ETV6, ALKBH3 | USP2 539/4885TSHR 3045/4885ALDH1A1 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.